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Despite considerable efforts to improve treatment modalities for osteosarcoma (OS), patient survival
remains poor mainly due to pro-survival pathways in OS cells. Among others, prostaglandins (PGs) are
the potent regulators of bone homoeostasis and OS pathophysiology. Therefore, the present study aimed
to elucidate the impact of 15-deoxy-D12,14-PGJ2 (15d-PGJ2, a stable PGD2 degradation product) on cell
death/cell survival pathways in p53-deficient MG-63 OS cells. Our findings show that 15d-PGJ2 induces
generation of reactive oxygen species that promote p38 MAPK activation and subsequent Akt
phosphorylation. This pathway induced nuclear expression of Nrf2 and Egr1, and increased transcription
of haem oxygenase-1 (HO-1) and the catalytic subunit of glutamate cysteine ligase (GCLc), catalysing the
first step in GSH synthesis. Silencing of Nrf2, Egr1 and HO-1 significantly elevated 15d-PGJ2-mediated
reduction of cellular metabolic activity. Activation of cell survival genes including HO-1 and GCLc
inhibited 15d-PGJ2-induced cleavage of pro-caspase-3 and PARP. Annexin V/propidium iodide staining
showed an increase in early/late apoptotic cells in response to 15d-PGJ2. The observed 15d-PGJ2-mediated
signalling events are independent of PGD2 receptors (DP1 and DP2) and PPARc. In addition, the
electrophilic carbon atom C9 is a prerequisite for the observed activity of 15d-PGJ2. The present data
show that the intracellular redox imbalance acted as a node and triggered both death and survival pathways
in response to 15d-PGJ2. Pharmacological or genetic interference of the pro-survival pathway, the p38
MAPK/Akt/Nrf2-Egr1/HO-1-GCLc axis, sensitizes MG-63 cells towards 15d-PGJ2-mediated apoptosis.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Osteosarcoma (OS), a tumour of mesenchymal origin, is the
most common tumour of bone. OS has a bimodal age distribution
being found predominantly in the second decade of life and in
elderly people. There are a variety of different types of OS tumours
that are associated with varying degrees of aggressiveness.
Although prognosis for OS patients has improved within last
decades, the highly metastatic potential renders this sarcoma
resistant to chemotherapeutic agents leading to dismal
perspectives for affected patients [1].Due to the complexity in the nature and diversity in the genetic
background, the exact aetiology of OS remains not fully under-
stood. Out of the known aetiological factors, cyclooxygenase and
its metabolites, the prostaglandins (PGs), play a pivotal role during
OS development and progression [2]. Among these prostanoids,
pro-inflammatory PGE2 has a predominant role in promoting
tumour growth and is assumed to be the most abundant PG found
in human bone metabolism and disease [3,4]. PGD2 can affect bone
metabolism by influencing both osteoclast and osteoblast func-
tions, both cells involved in bone remodelling and in vivo fracture
repair as well [3,5,6]. In osteoblasts PGD2 stimulated calcification
[7] and altered expression of RANKL and osteoprotegerin [6,8].
Furthermore, PGD2 favoured expression of cytokines via calcium
mobilization and Rho kinase [9,10], and promoted induction of
heat shock proteins via the mitogen-activated protein kinase
(MAPK) pathway [11,12].
However, PGD2 has a very short half-life [13] and is either
metabolized enzymatically to 13,14-dihydro-15-keto PGD2 [14]
or readily dehydrated into J series prostanoids with a
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15-deoxy-D12,14-PGJ2 (15d-PGJ2), the final dehydration product of
PGD2 has been shown to have wide-ranging effects on various
cellular systems [15,16].
15d-PGJ2 is a potent endogenous ligand for the peroxisome
proliferator-activated-receptor c (PPARc) (for a review see [17])
but may interact also with the PGD2 receptors DP1 and/or DP2.
15d-PGJ2 may modulate cell growth, viability and proliferation
and may induce cell death in further consequence. In murine
HL-1 cells and primary murine cardiomyocytes apoptosis was
mediated via DP2 [18], while in human umbilical vein endothelial
cells [19] and synoviocytes [20] 15d-PGJ2 induced apoptosis via
PPAR c-dependent mechanisms. PPARc-independent induction of
apoptosis has been reported in human B lymphocytes and B cell
lymphoma [21], human endothelial cells [22], rabbit synovial cells
[23], human hepatic myofibroblasts [24] and hepatocellular
carcinoma cell lines [25]. However, less information is available
on receptor-mediated (PPARc or DP1/DP2) apoptosis by 15d-PGJ2
in osteoblastic cells including OS cells [26–28].
Cell lines routinely used as models of OS have been derived from
OS tumours and are used to study the effects of growth and
specific bone-active factors as well as cytokines or prostanoids on
intracellular signalling cascades and apoptosis. In particular,
reactive oxygen species (ROS)-sensitive signalling pathways are
persistently elevated in many types of cancers. Cancer cells evolve
mechanisms to protect themselves from oxidative stress and
therefore may develop sophisticated adaption that essentially
involves hyperactivation of antioxidant signalling and upregulation
of pro-survival molecules. Therefore, identification and modulation
of survival pathways in OS cells, that may be responsible for
resistance against therapeutic agents, might help to improve
therapeutic outcome.
Among all the genetic aberrations occurring in OS, p53 is the
most frequently mutated (80–90%) or deleted (24–49%) gene [1].
Loss of functional transcription factor p53 is associated with redox
imbalance, increased oxidative stress, high mutagenesis and
aggressive tumour growth [29]. 15d-PGJ2 has been reported to
have dual effects, promoting either cell survival or inducing cell
death via apoptosis. The present study aimed to elucidate potential
pro-survival pathways in osteoblast-like MG-63 OS cells (deficient
of tumour suppressor protein p53) and to reveal whether gene
silencing and pharmacological interference may shift the balance
from cell survival to cell death in response to 15d-PGJ2 treatment.
2. Materials and methods
2.1. Cell culture
MG-63, a human OS cell line (ATCC, Manassas, VA, USA), was
maintained at 37 C under 5% CO2 in a-MEM medium (Invitrogen,
Lofer, Austria) supplemented with 5% (v/v) FCS [30] and 50 lg/ml
(w/v) gentamycin (Invitrogen). Cells were used between the 10th
and 20th passage counted from the day of receipt. If not otherwise
stated, cells were plated at a density of 2  105 in 6-well plates and
grown to 70% confluence [31].
2.2. Incubation protocols
MG-63 cells were treated with indicated concentrations of
15d-PGJ2 (Cayman, MI, USA) for indicated time periods. Cells
were incubated for 30 min with either an inhibitor of p38 MAPK
(25 lM PD169316, Merck Biosciences, Darmstadt, Germany),
N-acetyl-L-cysteine (NAC, 5 mM), pyrrolidine dithiocarbamate
(PDTC, 1 mM), N-2-mercaptopropionylglycine (MPG, 5 mM)
(Sigma–Aldrich, MO, USA), Tempol (1 mM, Tocris, MA, USA), PPARc
antagonist (20 lM T0070907), D-type prostanoid receptor (DP1)antagonist (100 nM MK0524), DP2 antagonist (1 lM CAY10471)
(Cayman), L-buthionine-(S,R)-sulfoximine (BSO, 5 lM), GSH ethyl
ester (10 mM, Sigma–Aldrich), LY294002 (10 lM) or Akt inhibitor
(Akt-I, 10 lM) (Calbiochem, CA, USA) prior to 15d-PGJ2 treatment.
Alternatively, cells were treated with 9,10-dihydro-15d-PGJ2
(dh-15d-PGJ2, 20 lM, Cayman) for indicated time periods.
2.3. Western blot analysis
(a) Whole cell proteins: MG-63 cells were lysed in ice-cold lysis
buffer (50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 10 mM Na4P2O7,
2 mM Na3VO4, 10 mM NaF, 1% [v/v] Triton X-100, 10% [v/v]
glycerol, pH 7.4, Sigma–Aldrich) containing a protease inhibitor
cocktail tablet (Roche, Vienna, Austria). Pellets were separated by
centrifugation at 13,000 rpm (4 C, 10 min).
(b) Cytosolic and nuclear proteins: For translocation experiments,
nuclear and cytosolic proteins were isolated using NE-PER
Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher
Scientific, IL, USA) with additional protease inhibitors (Complete
Mini protease inhibitor cocktail-tablets) according to the
manufacturer’s suggestions.
Protein estimation of whole cell, cytosolic and nuclear lysates
was performed using BCA protein assay kit (Thermo Fisher
Scientific). Whole cell (40 lg) or nuclear/cytosolic fraction (5 lg)
protein lysates were added to 10 ll of NuPAGE LDS sample buffer
(Invitrogen) containing 2 ll of NuPAGE sample reducing agent
(Invitrogen). After heating for 10min at 70 C proteins were separated
by electrophoresis on NuPAGE 4–12% Bis-Tris gel (Invitrogen) and
transferred to nitrocellulose membranes (Invitrogen, 0.45 lm).
Membranes were blocked with 5% (w/v) non-fat milk in TBST
(Tris-buffered saline containing Tween 20) (25 C, 2 h) and
incubated with primary antibodies (overnight at 4 C). The
following primary antibodies (diluted in 5% [w/v] BSA-TBST) were
used: anti-pp38 MAPK (1:1000 Cell Signaling-9211, MA, USA),
anti-pAkt T308 (1:1000 Cell Signaling-4056), anti-nuclear factor
(erythroid-derived 2)-like 2 protein (Nrf2) (1:1000 Santa
Cruz-sc722, TX, USA), anti-early growth response-1 (Egr1)
(1:1000 Santa Cruz-sc189), anti-HO-1 (1:333 Santa Cruz-sc10789),
anti-glutamate cysteine ligase-catalytic subunit (GCLc, 1:200 Santa
Cruz-sc166345), anti-GCL-modifier subunit (GCLm, 1:500 Santa
Cruz-166603), anti-caspase-3 (1:1000 Cell Signaling-9662) or
anti-Poly (ADP-ribose) polymerase (PARP) (1:1000 Biomol-SA250,
Hamburg, Germany). After washing, the membranes were
incubated with HRP-conjugated goat anti-mouse IgG (1:100,000
Biomol-8101102) or goat anti-rabbit IgG (1:200,000 Biomol-6293)
(25 C, 2 h). Immunoreactive bands were visualized using Super
Signal West Pico Chemiluminescent substrate (Thermo Fisher
Scientific) or Immobilon Western Chemiluminescent HRP substrate
(Millipore, Billerica, MA, USA) and developed by Bio-Rad ChemiDoc
MP Imaging System. For normalization, membranes were
stripped with stripping buffer (58.4 g/L NaCl, 7.5 g/L glycine, pH
2.15, Sigma–Aldrich) and incubated with anti-p38 (1:2000
Sigma–Aldrich-M0800), anti-Akt (1:500 Santa Cruz-sc1618R),
anti-Lamin (1:1000 Santa Cruz-sc20681), or anti-b-actin antisera
(1:1000 Santa Cruz-sc47778) as primary antibodies [30,32].
2.4. Annexin V/propidium iodide (PI) staining
MG-63 cells (70% confluent) were treated with 20 lM 15d-PGJ2
up to 48 h. Cells were harvested and stained using the FITC
Annexin V Apoptosis Detection Kit 1 (BD Biosciences, NJ, USA)
according to the manufacturer’s suggestion. Briefly, cells were
washed in cold PBS and incubated with 100 ll of 1x binding buffer
(containing 5 ll of Annexin V FITC and 5 ll of PI) for 15 min (25 C)
in the dark [33]. Flow cytometric analyses were performed on
Guava EasyCyte 8 (Millipore, Billerica, MA, USA) and analysed
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and gating for detection of necrosis and early/late apoptosis,
unstained and single stained cells were treated with staurosporine
(1 lM, 4 h, Sigma–Aldrich) or H2O2 (3 mM, 6 h, Herba Chemosan,
Vienna, Austria).
2.5. RNA isolation and quantitative real-time PCR (qPCR)
QIAshredder and RNeasy Mini Kit (Qiagen, Hilden, Germany)
were used to isolate RNA according to the manufacturer’s protocol.
After determining RNA concentration, one lg RNA was reverse
transcribed using High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA, USA) according to the
supplier’s manual. For gene quantification, six ng cDNA per
template was used with GoTaq qPCRMaster Mix (Promega, Vienna,
Austria) and gene specific primers. The qPCR protocol was
performed by LightCycler 480 system (Roche Diagnostics,
Vienna, Austria). The following gene specific primers were
used: GAPDH (Hs_GAPDH_1_SG), Nrf2 (Hs_NFE2L2_1_SG), Egr1
(Hs_EGR1_1_SG), HO-1 (Hs_HMOX1_1_SG) and GCLc
(Hs_GCLC_1_SG) (Qiagen). Relative gene expression levels were
normalized to GAPDH and calculated using DDCT method.
2.6. Gene silencing
MG-63 cells were transfected with siRNAs specific for Nrf2
(40 nM each, SI03246950, SI03246614, Qiagen), Egr1 (40 nM each,
SI00030709, SI03052511, SI03069108, SI03078950), HO-1 (40 nM
each, SI02780995, SI02780533) or scrambled negative controlFig. 1. Activation of p38 MAPK via intracellular redox imbalance in response to 15d-PGJ2
to follow pp38 MAPK expression using Western blot analysis. Cells were incubated wi
(Western blot analysis) and (C) DCF fluorescence as an indicator of the intracellular redox
30 min prior to 15d-PGJ2 treatment (20 lM) for 15 min to follow (D) ROS generation and (
One representative blot (A/B/E [upper panel]) out of three is shown. Densitometric eva
expressed as mean ± SEM (n = 3). For detection of intracellular ROS levels cells were incub
fluorescence intensity of vehicle (0.1% DMSO)-treated cells was set 100% and values aresiRNA (40 nM si-scr; Allstars negative control siRNA, Qiagen)
[18]. The siRNA transfection was performed using Lipofectamine
3000 (Invitrogen) according to the to the supplier’s manual. Briefly,
MG-63 cells (50% confluent) were transfected with 500 ll medium
(without FCS and gentamycin) containing 3 ll of Lipofectamine
3000 and the respective siRNA for 6 h at 37 C. Transfection medium
was replaced with medium (containing FCS and gentamycin) and
cells were grown for another 24 h. The mRNA expression levels
of silenced genes were measured using qPCR (see above). In
parallel, transfected cells were treated with 15d-PGJ2 to follow
protein expression usingWestern blot (see above) or cell metabolic
activity using the MTT assay (see below).2.7. Intracellular ROS measurement
Intracellular redox homoeostasis was assessed using carboxy-
H2DCFDA (5-(and -6)-carboxy-20,70-dichlorodihydrofluorescein
diacetate, Invitrogen), a cell-permeable dye that becomes
fluorescent upon oxidation by ROS. After treatment MG-63 cells
were incubated with 10 lMDCFDA in PBS for 30 min at 37 C. Cells
were washed twice with ice-cold PBS and lysed with 300 ll of 3%
(v/v) Triton X-100 in PBS (30 min) followed by addition of 50 ll
absolute ethanol (15 min) with shaking (1350 rpm, 4 C). Lysates
were centrifuged at 10,000 rpm (4 C, 10 min) to pellet debris.
The supernatants (100 ll) were used to measure DCF (20,70-dichlor
ofluorescein) fluorescence at emission/correction wavelengths of
485/540 nm, respectively [34]. A microtiter plate reader (Victor
Multilabel Counter, Perkin-Elmer, Waltham, MA, USA) was used
to measure fluorescence intensities.. (A) MG-63 cells were treated with indicated concentrations of 15d-PGJ2 for 10 min
th 15d-PGJ2 (20 lM) for indicated time periods to follow (B) p38 MAPK activation
balance. Cells were incubated with Tempol [1 mM], NAC [5 mM] or PDTC [1 mM] for
E) pp38 MAPK expression. Total p38MAPK expression was used as a loading control.
luation of immunoreactive bands is given below (A/B/E [lower panel]). Values are
ated with carboxy-H2DCFDA (10 lM) for 30 min after treatment with 15d-PGJ2. DCF
expressed as mean ± SEM (n = 6, C/D). *p 6 0.05 vs. control; #p 6 0.05 vs. 15d-PGJ2.
Fig. 2. 15d-PGJ2 promotes Akt phosphorylation via p38 MAPK activation. (A) MG-63 cells were treated with 15d-PGJ2 (20 lM) for indicated time periods to follow Akt
phosphorylation (pAkt, T308) using Western blot analysis. (B) Cells were incubated with PD169316 (25 lM), LY294002 (10 lM) or Akt-I (5 lM) for 30 min prior to 15d-PGJ2
treatment (20 lM) for 1 h to follow pAkt expression. For Western blot analysis total protein lysates were subjected to SDS–PAGE. Total Akt expression was used as loading
control. One representative blot (A/B [upper panel]) out of three is shown. Densitometric evaluation of immunoreactive bands is given below (A/B [lower panel]). Values are
expressed as mean ± SEM (n = 3). *p 6 0.05 vs. control; #p 6 0.05 vs. 15d-PGJ2.
Fig. 3. 15d-PGJ2 induces transcriptional activity of Nrf2 and Egr1 via the Akt axis. MG-63 cells were treated with 15d-PGJ2 (20 lM) for indicated time periods. Expression of
(A) Nrf2 and (B) Egr1 at mRNA (upper panel) and protein levels (middle panel) was followed using qPCR and Western blot analysis. (D) Cells were incubated with LY294002
(10 lM) or Akt-I (5 lM) for 30 min prior to 15d-PGJ2 treatment (20 lM) for 6 h to follow expression of Nrf2 and Egr1. (C) Alternatively, cells were treated with 15d-PGJ2
(20 lM) for indicated time periods to follow Nrf2 and Egr1 expression in cytosolic (left panel) and nuclear fractions (right panel). For Western blot analysis total protein
lysates were subjected to SDS–PAGE. Expression of b-actin (A–D) and lamin (C, lower panel) was used as loading controls. One representative blot out of three (A/B/D) or two
(C) is shown. Densitometric evaluation of immunoreactive bands is given below (A/B/D [lower panel]). Values (A/B/D) are expressed as mean ± SEM (n = 3). RNA was isolated
and qPCR was performed using specific primers. Values are expressed as mean ± SEM (n = 6). *p 6 0.05 vs. control and #p 6 0.05 vs. 15d-PGJ2.
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Fig. 4. Activation of HO-1 and GCLc in response to 15d-PGJ2 treatment. MG-63 cells were treated with 15d-PGJ2 (20 lM) for indicated time periods. Expression of (A) HO-1 at
mRNA (upper panel) and protein levels (middle and lower panels) was followed using qPCR and Western blot analysis, respectively. Alternatively, (B) cells were incubated
with LY294002 (10 lM) or Akt-I (5 lM) for 30 min prior to 15d-PGJ2 treatment. Next, cells were transfected with scrambled siRNA (si-scr, negative control) (40 nM) or
specific siRNA against Nrf2 (si-Nrf2, 40 nM, C) or Egr1 (si-Egr1, 40 nM, D). Transfected (C/D) and pretreated (B) cells were stimulated with 15d-PGJ2 (20 lM) for 6 h to follow
HO-1, GCLc and Nrf2/Egr1 expression (B–D). b-Actin expression was used as a loading control. One representative blot (A–D) out of three is shown. Densitometric evaluation
of immunoreactive bands is given below (A–D [lower panel]). Values are expressed as mean ± SEM (n = 3). *p 6 0.05 vs. control; #p 6 0.05 vs. 15d-PGJ2.
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MG-63 cells (70% confluent) were treated with 15d-PGJ2
followed by incubation with MTT (3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide) (0.5 mg/ml; dissolved in serum-
free medium) for 30 min at 37 C. The converted insoluble dark
purple coloured dye (formazan) was solubilized by an addition of
300 ll acidic isopropanol (0.04 M HCl in isopropanol) [34]. Cell
metabolic activity was determined by measuring optical densities
at emission/correction wavelengths of 570/630 nm, respectively,
by a microtiter plate reader (see above).2.9. Glutathione assay
Intracellular glutathione was determined using a commercial
Glutathione Assay Kit (Cayman) according to the manufacturer’s
protocol. Briefly, after treatment cells were washed twice with cold
PBS and scraped in 1 ml PBS (pH 7.0) containing 1 mM EDTA. Cells
were homogenized by sonication followed by deproteination
with 5% metaphosphoric acid. Total GSH levels were determined
according to the manufacturer’s instruction and absorbance was
measured at 405 nm (Multiscan FC microplate photometer,
Thermo Fisher Scientific). Absorbance values from standards and
Fig. 5. 15d-PGJ2 elevates GCLc expression and GSH production in a receptor-independent manner. (A) MG-63 cells were treated with 15d-PGJ2 (20 lM) for indicated time
periods to follow GCLc expression at mRNA (upper panel) and protein levels (middle and lower panels) using qPCR and Western blot, respectively. (B) MG-63 cells were
treated with 15d-PGJ2 (20 lM) for indicated time periods to follow GCLm expression at protein levels using Western blot analysis. (C) Alternatively, cells were treated with
15d-PGJ2 (20 lM) for indicated time periods to follow GSH production. (D) MG-63 cells were treated with indicated inhibitors for 30 min or prior to 15d-PGJ2 treatment
(20 lM) for 6 h to follow expression of HO-1 and GCLc using Western blot analysis. b-Actin expression was used as a loading control. One representative blot out of two is
shown. Densitometric evaluation of immunoreactive bands is given below (A [lower panel]). Values are expressed as mean ± SEM (n = 6). *p 6 0.05 vs. control. As membranes
for GCLc (A) were stripped and reprobed with anti-GCLm antibodies (B), the same b-actin blot is shown.
34 C.N. Koyani et al. / Biochemical Pharmacology 104 (2016) 29–41samples were subtracted with blank control values and GSH
concentrations of samples were calculated by interpolation from
standard curve. Results were expressed as lmoles of total GSH
normalized to 106 cells [30].
2.10. Statistical analysis
All values are represented as mean or mean ± SEM and n
represents the number of experiments. Statistical significances
were tested by Student’s t-test or a one-way ANOVA with adequate
post hoc tests (Tukey or Dunett), using IBM SPSS 20 software. The
p-values 6 0.05 were considered statistically significant. All tests
were 2-sided.
3. Results
3.1. 15d-PGJ2 induces phosphorylation of p38 MAPK in human OS cells
As 15d-PGJ2 has been reported to promote phosphorylation of
MAPKs in various cell lines [18,30,35], we concentrated on
expression of pp38 MAPK in MG-63 cells. Addition of 15d-PGJ2
to cells induced p38 MAPK phosphorylation concentration-
dependently with an adequate phosphorylation at 20 lM
concentration (Fig. 1A) that is used for all further experiments.
Fig. 1B shows time-dependent phosphorylation of p38 MAPK up
to 30 min; maximum phosphorylation was observed from 15 min.
3.2. 15d-PGJ2 alters intracellular redox balance
Cellular treatment by cyclopentenone PGs may induce ROS
generation that co-induces alterations in intracellular signallingcascades [18,30]. To clarify whether 15d-PGJ2 affects redox
homoeostasis in MG-63 cells the redox-sensitive probe DCFDA
was used. In response to 15d-PGJ2 time-dependent increase in
DCF fluorescence reached a maximum from 7.5 min with levels
elevated approximately 1.7-fold over baseline (Fig. 1C).
Next, we tested the efficacy of scavengers of various reactive
species. To interfere intracellular redox homoeostasis, Tempol (a
superoxide dismutase mimetic), PDTC (a NO synthase inhibitor)
and NAC (preferentially reacting with reactive oxygen and nitrogen
species) were used. Among these compounds only Tempol blunted
DCF-fluorescence (Fig. 1D) and subsequent phosphorylation of p38
MAPK (Fig. 1E) in response to 15d-PGJ2 treatment. These data
reveal that the formation of reactive species is an upstream event
of p38 MAPK activation.
3.3. Phosphorylation of AKT via p38 MAPK activation in response to
15d-PGJ2
Fig. 2 shows that 15d-PGJ2 treatment resulted in transient
phosphorylation of Akt (T308) reaching a plateau from 2 h
(Fig. 2A). Pretreatment of cells with PD169316 (a p38 MAPK
inhibitor), LY294002 (an inhibitor of PI3K/Akt) as well as Akt-I
(an Akt inhibitor) prevented Akt phosphorylation (Fig. 2B). These
results indicate that 15d-PGJ2-induced phosphorylation of Akt
depends on the activation of p38 MAPK and PI3K.
3.4. Activation of Egr1 and Nrf2 via p38 MAPK/Akt signalling in
response to 15d-PGJ2
Next, we tested whether 15d-PGJ2 promotes induction of tran-
scriptional factors via the PI3K/Akt pathway. Indeed, 15d-PGJ2
Fig. 6. 15d-PGJ2 alters cellular metabolic activity and induces caspase-3 and PARP
cleavage in MG-63 cells. Cells were treated with 15d-PGJ2 (20 lM) for indicated
time periods to follow (A) cellular metabolic activity (using the MTT assay).
Metabolic activity (%) of vehicle (0.1% DMSO)-treated cells was set 100% and values
are expressed as mean ± SEM (n = 6). *p 6 0.05 vs. control. (B) In parallel, caspase-3/
PARP cleavage was followed by Western blot experiments. b-Actin was used as a
loading control. One representative blot out of three is shown. Densitometric
evaluation of immunoreactive bands is given below (lower panel). Values are
expressed as mean ± SEM (n = 6). *p 6 0.05 vs. control. Pro-caspase-3 (p-Caspase-3,
molecular mass: 35 kDa); cleaved caspase-3 (c-Caspase-3; molecular mass: 19 and
17 kDa). Poly (ADP-ribose) polymerase (PARP; molecular mass: 116 kDa; cleaved
PARP; molecular mass: 89 kDa).
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Egr1 (1 h) expression at mRNA level (Fig. 3A/B; upper panel). This
was accompanied by an increase of Nrf2 and Egr1 protein, which
lagged approximately 2 h behind mRNA levels (Fig. 3A/B; middle
and lower panels). Western blot analysis of Nrf2 and Egr1 showed
only faint cytosolic expression but intense signals in the nuclear
fraction after 1 h (Nrf2) or 2 h (Egr1) in response to 15d-PGJ2
(Fig. 3C, left and right panels, respectively). Pretreatment of
MG-63 cells with LY294002 and Akt-I prevented induction
of Nrf2 and Egr1 (Fig. 3D). These results demonstrate that
15d-PGJ2-induced expression of Nrf2/Egr1 is mediated via the
p38 MAPK/PI3K/Akt axis.
3.5. Activation of HO-1 and GCLc in response to 15d-PGJ2
The 50-untranslated region of HMOX1 (the gene encoding
human HO-1) contains antioxidant-response elements (AREs) that
can bind the transcription factor Nrf2. Thereby Nrf2 elevates
oxidative-stress-induced transcription of HO-1. Fig. 4A shows a
time-dependent increase of HO-1 transcription (upper panel) and
translation (middle and lower panels) in response to 15d-PGJ2.
Incubation of MG-63 cells with LY294002 or Akt-I prior to
15d-PGJ2 treatment significantly impaired HO-1 expression (Fig. 4B).
Silencing of Nrf2 or Egr1 with specific siRNAs significantly decreased
immunoreactive HO-1 bands to almost baseline levels (Fig. 4C/D).
The protective gene GCL is under control of the transcriptional
ARE of Nrf2 [36]. 15d-PGJ2 treatment resulted in a time-
dependent increase of GCLc on mRNA (Fig. 5A, upper panel) and
protein levels (Fig. 5A, middle and lower panels), while expression
of GCLm (the modifier subunit of GCL) was unaffected by 15d-PGJ2
treatment (Fig. 5B). To demonstrate catalytic activity of GCLc intra-
cellular GSH levels were quantitated by the Glutathione Assay kit.
Time-course experiments show an increase of GSH levels reaching
a plateau from 12 h (Fig. 5C). Preincubation of cells with LY294002
and Akt-I prior to 15d-PGJ2 treatment blunted GCLc expression
(Fig. 4B). Most importantly, silencing of Nrf2 or Egr1 decreased
immunoreactive GCLc bands almost to baseline levels (Fig. 4C/D).
Next, we aimed to elucidate whether 15d-PGJ2-mediated sig-
nalling occurs via receptor-dependent or -independent interaction.
15d-PGJ2 is considered as a potent endogenous ligand for PPARc, a
member of the nuclear receptor superfamily of ligand-dependent
transcriptional factors. T0070907 (a PPARc antagonist) was unable
to inhibit 15d-PGJ2-induced HO-1 and GCLc expression (Fig. 5D).
Then, we tested a possible involvement of PGD2 receptors DP1
and DP2 (the latter also named CRTH2, the chemoattractant
receptor-homologous molecule expressed on Th2 cells), which
are reported to interact with 15d-PGJ2 [18,37]. Of note, neither
MK0524 (a DP1 antagonist) nor CAY10471 (a DP2 antagonist)
altered expression levels of HO-1 and GCLc proteins in response
to 15d-PGJ2 (Fig. 5D).
3.6. 15d-PGJ2 impairs metabolic activity and promotes cell death
Next, the MTT assay was performed to assess cell metabolic
activity [38]. This colorimetric assay revealed a decrease of meta-
bolic activity of MG-63 cells by 60% (24 h) and 80% (48 h) after
15d-PGJ2 treatment (Fig. 6A), data in line with previous findings
[30].
We tested whether these alterations are paralleled by induction
of apoptosis. Pronounced immunoreactive bands of the respective
cleavage product, caspase-3 (17 and 19 kDa) became apparent
after 24 h (Fig. 6B). Activation of caspase-3 (the convergence point
of the extrinsic and intrinsic apoptotic pathway) is the prerequisite
for apoptotic cell death. Fig. 6B shows that 15d-PGJ2 also promoted
PARP cleavage (89 kDa), a downstream event of pro-caspase-3
cleavage.To confirm that MG-63 cells undergo apoptosis, flow cytometry
analyses using Annexin V/PI staining were performed. Fig. 7A
shows representative scatter plots of MG-63 cells treated with
15d-PGJ2 up to 48 h; staurosporine was used as a positive control
to induce apoptosis. Fig. 7B summarizes the percentage of living,
early/late apoptotic and necrotic cells. In vehicle-treatment group
the number of early and late apoptotic cells was 11% and 3%,
respectively. Time-dependent treatment with 15d-PGJ2 signifi-
cantly increased the percentage of early and late apoptotic cells
up to 20% and 11%, respectively, after 48 h. The time-dependent
decrease of living MG-63 cells (Fig. 7B) coincides with decreased
MTT reduction (Fig. 6A) and activation of pro-caspase-3 and PARP
(Fig. 6B).3.7. The Nrf2/Egr1-HO-1/GCLc axis is a cell survival pathway
protecting against 15d-PGJ2-induced apoptosis
Next, we addressed possible survival pathways against
15d-PGJ2-induced cell death in MG-63 cells. Performing the MTT
assay we show that silencing of transcriptional factors Nrf2 and
Egr1, as well as their downstream target, HO-1, with the specific
siRNAs decreased cellular metabolic activity of 15d-PGJ2-treated
cells (Fig. 8A). Western blot experiments confirm that silencing
of HO-1 increases cleavage of pro-caspase-3 and PARP in response
to 15d-PGJ2 (Fig. 8B).
Fig. 7. Induction of apoptosis in MG-63 cells by 15d-PGJ2. Cells were treated with 20 lM 15d-PGJ2 for indicated time periods (A/B) or 1 lM staurosporine for 4 h as a positive
control. The cells were trypsinized, stained with Annexin V FITC and propidium iodide (PI) and analysed by flow cytometry. Cells in the lower left quadrant represent living
cells while cells in the upper left quadrant represent necrotic cells (Annexin/PI+). Cells in the lower right quadrant represent early apoptotic cells (Annexin+/PI), and cells in
the upper right quadrant represent late apoptotic cells (Annexin+/PI+). To set up fluorescent compensation and gating, unstained and single stained positive controls (1 lM
staurosporine [4 h] or 3 mM H2O2 [6 h]) were used. (B) The bar graph summarizes the percentage of all four-cell populations (A) from three independent experiments
performed in triplicate. Values are given as mean.
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inhibitor of GCL [39]) prior to 15d-PGJ2 treatment. Similar to
the silencing approach, BSO-pretreatment decreased cellular
metabolic activity (Fig. 8A). In line, Western blot experiments
reveal a more pronounced cleavage of pro-caspase-3 and PARP
when compared to cells treated with 15d-PGJ2 alone (Fig. 8C).
Next, MG-63 cells were preincubated with GSH ethyl ester to
increase intracellular GSH levels. Indeed, GSH pretreatment
protected MG-63 cells against 15d-PGJ2-induced depletion of
metabolic activity (Fig. 8A) and cleavage of pro-caspase-3 and
PARP (Fig. 8D).
We were further interested whether interference with the
intracellular redox balance would affect cell survival pathways.
Fig. 9A (upper panel) shows that DCF fluorescence was reduced
to baseline levels when cells were preincubated with GSH ethyl
ester. In parallel, expression of Nrf2/Egr1 and HO-1/GCLc was
significantly reduced in response to GSH ethyl ester (Fig. 9A;
middle and lower panels). As an alternative approach, MG-63 cells
were pretreated with MPG, a precursor for intracellular GSHsynthesis. MPG decreased DCF-fluorescence (Fig. 9A; upper panel)
and protein expression of Nrf2/Egr1 and HO-1/GCLc (Fig. 9A;
middle and lower panels) in response to 15d-PGJ2.
Finally, data in Fig. 9B show that pretreatment of MG-63 cells
with 5 mM MPG blunted 15d-PGJ2-induced cleavage of
pro-caspase 3 and PARP.
3.8. Effects of dh-15d-PGJ2, the structural analogue of 15d-PGJ2
To prove that the C9 electrophilic carbon atom of 15d-PGJ2 (for
structure, see Fig. 10A, [16]) is a prerequisite for 15d-PGJ2-mediated
signalling, we included dh-15d-PGJ2, a structural analogue of
15d-PGJ2 lacking the a,b-unsaturated ketone structural element
(Fig. 10A) [18,30]. We have previously shown in MG-63 cells that
dh-15d-PGJ2 did not induce ROS formation, an apparent prerequisite
for MAPK activation [30]. Here, we show that in contrast to
15d-PGJ2, dh-15d-PGJ2 did neither induce phosphorylation of
p38 MAPK/Akt, expression of Nrf2/Egr1 and HO-1/GCLc nor cleavage
of pro-caspase-3/PARP in MG-63 cells (Fig. 10B–F).
Fig. 8. The Nrf2/Egr1-HO-1/GCLc axis protects cells against 15d-PGJ2-induced cell death. Cells were treated with 15d-PGJ2 (20 lM) for indicated time periods to follow (A)
cellular metabolic activity (using the MTT assay). Metabolic activity (%) of vehicle (0.1% DMSO)-treated cells was set 100% and values are expressed as mean ± SEM (n = 6).
MG-63 cells were transfected with scrambled siRNA (si-scr) (40 nM), siRNA against HO-1 (si-HO-1, A/B), Nrf2 (si-Nrf2, A) or Egr1 (si-Egr1, A) (40 nM). Alternatively, cells were
incubated with BSO (5 lM, A/C) or GSH (10 lM, A/D) for 30 min prior to 15d-PGJ2 treatments. Transfected (A/B) and pretreated (A/C/D) cells were treated with 15d-PGJ2
(20 lM) to follow HO-1 expression (B, 6 h), caspase-3/PARP cleavage (B/C/D, 24 h) or metabolic activity (D, 24 h). b-Actin expression was used as a loading control. One
representative blot out of three is shown. Densitometric evaluation of immunoreactive bands is given below (B/C/D [lower panel]). *p 6 0.05 vs. control and #p 6 0.05 vs.
15d-PGJ2. Pro-Caspase-3 (p-Caspase-3); cleaved Caspase-3 (c-Caspase-3). Poly (ADP-ribose) polymerase (PARP; uncleaved and cleaved forms).
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Increased production of ROS is the characteristic of a metabolic
shift observed during malignant transformation. Therefore, main-
taining redox balance is crucial for cancer cell survival and might
be exploited pharmacologically [29,40]. However, redox alteration
in cancer cells is complex and addition of ROS-generating agents
may not always lead to preferential cell killing. Cancer cells may
become well adapted to stress and may develop a selective,
endogenous antioxidant defence system to promote cell prolifera-
tion and evade apoptosis [29,40,41]. Therefore, we were interested
if such a mechanism operates in OS and whether modulation of
these pathways elevates apoptosis.
Here, we present evidence for the induction of the Nrf2-Egr1/
HO-1-GCLc signalling pathway in response to 15d-PGJ2 in MG-63
cells. Genetic or pharmacological interference at specific steps of
this pathway modulated cell metabolic activity and cleavage ofpro-caspase-3 and PARP (a hallmark of apoptosis). To the best of
our knowledge we are the first to show that activation of the
MAPK/Akt/Nrf2-Egr1/HO-1-GCLc axis provides an adaptive
survival response of MG-63 OS cells against 15d-PGJ2-induced
treatment (Fig. 11). Most importantly, the observed effects are
independent of PPARc and PGD2 receptors, DP1 and DP2.
The lipocalin-type PGD2 synthase is abundantly expressed in
primary osteoblasts and MG-63 cells [6,42] and both cells
synthesize PGD2 in vitro in response to various stimuli [6]. As an
autacoid, PGD2 can act on DP1 and DP2 receptors, both present
on osteoblasts and MG-63 [6] as well osteoclasts [43]. In the latter
cell type PGD2-induced apoptosis was exclusively mediated by the
DP2-p42/44 MAPK-Akt axis without involvement of DP1 [5,44].
However, PGD2 is rapidly metabolized into PGs of the J-series;
therefore it is reasonable to assume that 15d-PGJ2 is most likely
responsible for the effects observed with its parent PG. While a
series of reports addressed PPARc-independent activities of
Fig. 9. Effect of GSH and MPG on the Nrf2/Egr1-HO-1/GCLc axis and cell death induced by 15d-PGJ2. MG-63 cells were treated with (A/B) MPG or (A) GSH ethyl ester (termed
GSH) for 30 min or prior to 15d-PGJ2 treatment (20 lM) for 15 min (A, upper panel), 6 h (A, middle panel) or 24 h (B) to follow (A, upper panel) ROS generation by measuring
DCF fluorescence and expression of (A, middle panel) Nrf2, Egr1, HO-1 and GCLc, and (B) apoptotic markers using Western blot analysis. b-Actin was used as a loading control.
One representative blot out of three is shown. Densitometric evaluation of immunoreactive bands is given below (A/B [lower panel]). (A) DCF fluorescence intensity of vehicle
(0.1% DMSO)-treated cells was set 100% and values are expressed as mean ± SEM (n = 6). *p 6 0.05 vs. control and #p 6 0.05 vs. 15d-PGJ2. Pro-Caspase-3 (p-Caspase-3);
cleaved Caspase-3 (c-Caspase-3). Poly (ADP-ribose) polymerase (PARP; uncleaved and cleaved forms).
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receptor-mediated downstream cellular signalling and apoptosis.
In cardiomyocytes 15d-PGJ2 promoted inflammation and
apoptosis via the DP2/MAPK/TNF a axis [18], while in murine
oligodendrocytes [45] and human MG-63 cells (Fig. 5B) neither
DP1 nor DP2 receptor was involved.
15d-PGJ2 is highly reactive [16,17] and rapidly gets inactivated
by the components of cell culture medium, and therefore the
concentrations of 15d-PGJ2 used under in vitro conditions are
much higher than those of estimated under in vivo conditions
[37]. Furthermore, estimated in vivo levels of 15d-PGJ2 represent
only the freely available (but not protein-/thiol-inactivated)
eicosanoid. Therefore, we have used a concentration of 20 lM
15d-PGJ2 as a bolus in the present vitro study. Moreover, it is worth
mentioning that primary cells are muchmore sensitive to 15d-PGJ2
treatment compared to immortalized cell lines [18].
In line with our previous data, we show that 15d-PGJ2 rapidly
initiates phosphorylation of p38 MAPK in MG-63 cells (Fig. 1A/B)
while pronounced activation of p42/44 MAPK occurred from 4 h
[30]. In addition, we show that altered redox homoeostasis is the
trigger for p38 MAPK activation (Fig. 1C/D), which in turn
promoted Akt phosphorylation (Fig. 2). Indeed, the PI3K/Akt
pathway is considered as one of the most important pro-survival
pathways in human OS (for a review see [46]). Since Akt promotes
survival of cancer cells even under adverse conditions and during
chemotherapy, hyperactivated Akt in OS represents the platformfor disease initiation and propagation. Activation of the PI3K/Akt
axis in cancer cells promotes cell cycle progression, invasion,
proliferation, angiogenesis, tumourigenesis and metastasis but
inhibits apoptosis. Therefore, modulation of the PI3/Akt axis could
represent a therapeutic option [46]. Results of the present study
demonstrate that LY294002 (PI3K/Akt) and Akt-I effectively
blocked survival signalling in MG-63 cells via the ARE pathway
(Figs. 2 and 4). Previously, inhibition of Akt by natural compounds
e.g. Grifolin and Oridonin has been reported to induce caspase-
dependent apoptosis in OS cells [47,48]. Moreover, Miwa and
colleagues [49] reported that caffeine induces apoptosis in OS cells
via activation of PTEN (phosphatase and tensin homologue), a
negative regulator of PI3K-Akt signalling.
Following endogenous or exogenous oxidative stress response,
sequential activation of MAPK and Akt induces expression of
Egr1 and Nrf2. While expression of Egr1 and downstream targets
is linked to cell cycle regulation, growth, proliferation and
migration, an active Nrf2 pathway maintains redox balance in
cancer cells in a range that favours cell growth and survival [50].
Thus, Nrf2 and its downstream target(s) including HO-1 appear
to induce chemoresistance in cancer cells. In contrast, Egr1
regulates HO-1 expression in various cells/tissues [51,52] but no
report is available for OS cells. Under unstressed conditions,
expression of HO-1 in osteoblasts is very low [53]. In line, our
results show almost no detectable HO-1 protein in OS cells under
non-stimulated conditions (Fig. 4A). However, overexpression of
Fig. 10. The chemical structure of (dh-)15d-PGJ2 and possible activation cascades. (A) The chemical structure of 15d-PGJ2 and dh-15d-PGJ2 (9,10-dihydro-15d-PGJ2, *indicates
electrophilic carbon atom). (B–F) MG-63 cells were stimulated with dh-15d-PGJ2 (20 lM) or 15d-PGJ2 (20 lM, used as a positive control) for (B) 15 min to follow
phosphorylation of p38 MAPK, (C) 1 h to follow phosphorylation of Akt, (D) 6 h to follow Nrf2 and Egr1 expression, (E) 6 h to follow HO-1 and GCLc expression or (F) 24 h to
follow cleavage of pro-caspase and PARP. For Western blot analysis total protein lysates were subjected to SDS–PAGE. (B) Total p38 MAPK, (C) total Akt, and (D–F) b-actin
were used as loading controls. One representative blot out of two is shown. Pro-caspase-3 (p-Caspase-3, molecular mass: 35 kDa); cleaved caspase-3 (c-Caspase-3; molecular
mass: 19 and 17 kDa). Poly (ADP-ribose) polymerase (PARP; molecular mass: 116 kDa; cleaved PARP; molecular mass: 89 kDa). As membranes for Nrf2/Egr1 (D) were
stripped and reprobed with anti-HO-1/-GCLc antibodies (E), the same b-actin blot is shown.
Fig. 11. Schematic presentation of cell survival and cell death signalling cascades in
MG-63 osteosarcoma cells following treatment with 15d-PGJ2.
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importantly, HO-1 upregulation protects mesenchymal stem cells[55] and cancer cells [56] against chemotherapeutic compounds.
Inhibition of HO-1 increases responsiveness of pancreatic cancer
cells against chemotherapy [57] and elevates apoptosis-induced
cell death in MG-63 cells (Fig. 7B). Indeed, silencing of Nrf2, Egr1
and HO-1 (Fig. 8A) must be considered an effective approach to
impair survival signalling of MG-63 OS cells.
The GSH redox and detoxification system is a critical cellular
homoeostatic mechanism [58]. When cancer cells internalize
anti-neoplastic drugs they might be conjugated with GSH and
metabolized. Thus elevated GSH levels or increased activity of GCLc
as observed here can decrease drug efficacy. The first and rate-
limiting step in GSH synthesis is catalysed by GCL, a heterodimeric
protein composed of GCLc and GCLm subunits both expressed by
separate genes. GCLc exhibits all of the catalytic activity while
GCLm is inactive but regulates the reaction rate and catalytic
activity of GCLc to produce GSH [59]. Transcription of GCLc and
GCLm is under control of the ARE pathway and expression of
Nrf2 and GCLc in sarcoma tissues suggests that this protective
pathway might be active in most sarcomas [60]. While only little
information is available about interaction of Egr1 with GCLc
promoter [61], our data confirm the regulation of GCLc expression
via transcriptional factor Egr1 in MG-63 OS cells (Fig. 4D). In the
pheochromocytoma PC12 cell line both GCL subunits were
upregulated in response to 15d-PGJ2 [62]. In contrast, oxidative
stress conditions appear to induce selectively the transcription of
GCLc subunit in human hepatocellular carcinoma [62]. These data
are in line with our findings where 15d-PGJ2 specifically increases
GCLc protein and intracellular GSH levels in MG-63 OS cells.
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15d-PGJ2 acts as an endogenous electrophile. 15d-PGJ2 may form
covalent protein adducts via Michael addition with cellular
nucleophiles, such as thiol groups of proteins [63]. In comparison
to other reactive aldehydes like 4-hydroxynonenal or acrolein,
15d-PGJ2 is less reactive but displays higher target specificity
[64]. This is of relevance for the present study, since 15d-PGJ2
induces ARE via covalent thiol-modification in Keap1. Under basal
conditions two molecules of Keap1 interact with one Nrf2
molecule where Keap1 functions as an adaptor protein in the
Cullin3-based E3 ligase system that facilitates ubiquitination and
proteasomal degradation of Nrf2 [65]. 15d-PGJ2 modifications at
thiol residues induce a conformational change in Keap1,
displacement of the DLG motif, leading to the escape of Nrf2 from
proteasomal degradation. In this electrophile-activated setting,
Nrf2 translocates to the nucleus, binds to ARE (following
dimerization with small Maf proteins) and induces downstream
target gene transcription including HO-1, GCLm, and GCLc [65].
Our observation that dh-15d-PGJ2 (lacking the endocyclic double
bond) is unable to reproduce the biological activities of 15d-PGJ2
(Fig. 10) supports the concept of covalent electrophile modification
during ARE induction in MG-63 cells.
During the present study we chose two different experimental
approaches to modulate intracellular GSH levels namely (i) to
provide extracellular cell-permeable precursors (GSH ethyl ester
and MPG) and (ii) to pharmacologically inhibit GCLc with BSO.
Due to the ability of 15d-PGJ2 to form covalent adducts with thiols
(see above) we cannot exclude that some 15d-PGJ2 is scavenged by
GSH ethyl ester and/or MPG in the cellular supernatant thus
reducing active 15d-PGJ2. BSO, an inhibitor of cellular GSH
synthesis, significantly augmented the apoptotic potential of
15d-PGJ2 towards MG-63 cells. This is reminiscent of what was
reported for andrographolide-treated hepatoma cells [66] or
Cisplatin-treated OS cells [67].
Tumour suppressor p53 is the most frequently mutated/deleted
gene in OS [1,68]. Therefore, we have used MG-63 cells (that
lack p53) as a suitable and representative OS cell model. Our
data reveal that ROS generated by 15d-PGJ2 in MG-63 cells
induces apoptosis in a p53-independent manner. Alternatively,
retinoblastoma (Rb) protein (expressed in MG-63 [69]), that
controls activation of the E2F transcription factor family, might be
involved in the observed cell death signalling. In particular, E2F1
is known to induce apoptosis via p53-independent pathways and
to regulate expression of various genes that play pivotal role in
the apoptotic machinery and DNA damage [70]. Furthermore, Rb
interacts with PTEN that modulates phosphorylation of Akt via
PDK, an important cancer survival pathway including OS. Another
mode of action could involve inhibition of anti-apoptotic activity
of the transcriptional factor NF-jB by 15d-PGJ2. In ovarian cancer
cells 15d-PGJ2 inhibited NF-jB activity in a concentration-
dependent manner, whereby complete inhibition was observed at
20 lM [71], a concentration that was used also in the present
study. As 15d-PGJ2-induced ROS formation has been reported to
inhibit NF-jB activity in endothelial cells [72], this pathway might
be operative to induce 15d-PGJ2-mediated apoptosis in MG-63 cells
after 24 h.
In conclusion, our data provide a framework for the
construction of cell death and cell survival pathways in MG-63
OS cells in response to 15d-PGJ2 (Fig. 11). The survival pathway
originates from p38 MAPK activation that extends to
Akt-mediated translocation of Nrf2/Egr1 to the nucleus and
upregulation of HO-1/GCLc expression. HO-1 and GSH protected
cells against 15d-PGJ2-induced pro-caspase-3 and PARP cleavage
and cell death. Silencing of Nrf2, Egr1 and HO-1, and inhibition
of GSH synthesis by BSO sensitized MG-63 cells towards
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